Navigation Links
Rigel Announces Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

$3,128 $12,600 $33,473

Operating expenses:

Research and development

(see Note A) 21,960 15,002 70,364 56,968

General and administrative

(see Note A) 6,297 5,020 21,763 19,552

Total operating expenses 28,257 20,022 92,127 76,520

Loss from operations (20,257) (16,894) (79,527) (43,047)

Interest income, net 1,255 1,438 5,255 5,410

Net loss $(19,002) $(15,456) $(74,272) $(37,637)

Net loss per common share, basic

and diluted $(0.61) $(0.62) $(2.57) $(1.51)

Weighted average shares used in

computing net loss per common

share, basic and diluted 31,084 25,093 28,936 24,936

Note A

Stock-based compensation expense

included in:

Research and development $1,307 $1,317 $5,519 $6,515

General and adminstrative 1,259 1,125 6,168 6,064

$2,566 $2,442 $11,687 $12,579

SUMMARY BALANCE SHEET DATA

(in thousands)

December 31, December 31,

2007 2006(1)

(unaudited)

Cash, cash equivalents and

available for sale securities $108,296 $104,471

Total assets 115,789 113,240

Stockholder's equity 82,182 87,229

(1) Derived from audited financial statements


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Rigel Announces Pricing of Public Offering of Common Stock
4. Rigel to Present at BIO CEO & Investor Conference
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... SHANGHAI, China, Jan. 31 /Xinhua-PRNewswire/ -- WuXi ... its acquisition of AppTec Laboratory,Services, Inc., a ... device industries. AppTec offers testing, contract research ... a highly,differentiated, fully integrated platform., (Logo: ...
... (Nasdaq: DRRX ) fourth quarter 2007 financial,results press release, you ... live over the Internet on Wednesday, February 6,2008 at 9:00 a.m. ... 6, 2008 at 9:00 a.m. EST (6:00 a.m. PST). Where: ... http://www.durect.com, ...
... AMLN ) will be presenting at the Merrill ... York on,Wednesday, February 6, 2008 at 1:00 p.m. ET ... Finance and Chief Financial Officer of,Amylin Pharmaceuticals, will be ... breakout session will be webcast, and a,recording will be ...
Cached Biology Technology:WuXi PharmaTech Completes Acquisition of AppTec 2
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... Department of Agriculture; and the University of Haifa in Israel ... protein, zinc and iron content in the grain, potentially offering ... children around the world. , Results from the study will ... Science. , "Wheat is one of the world's major ...
... pictures made the cover of Nature in 1998, were ... appears, they may have been. , This week, a ... reinterpreting the 600 million-year-old fossils from the Precambrian era ... understanding of microfossils thought to be the oldest animals," ...
... hunts begin in the Japanese villages of Taiji and Futo, ... has launched a campaign to end the practices through public ... put an end to the hunts. The "Act for Dolphins" ... and the World Association of Zoos and Aquariums (WAZA) --maintains ...
Cached Biology News:Wheat gene may boost foods' nutrient content 2Oldest animal fossils may have been bacteria 2Renewed dolphin slaughter prompts new campaign 2Renewed dolphin slaughter prompts new campaign 3
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
HSPBP1 Antibody...
... CRE-bla HEK 293T cell line contains the ... cAMP response element (CRE). To obtain the ... into HEK 293T cells by lentivirus. Subsequent ... responsive to forskolin stimulation (Figure 1). The ...
Biology Products: